Resistin, a proinflammatory cytokine, is elevated in a number of pathological disorders, including cancer. The serum resistin level in colon cancer patients is elevated and correlates with tumor grade. However, the implications of increased resistin on colon cancer cells remain unclear. In the present study, we find that resistin binds to TLR4 on colon cancer cell membrane and initiates TLR4-MyD88-dependent activation of ERK. In addition, the upregulation of SOCS3 by ERK downregulates the JAK2/TAT3 pathway and causes the arrest of cells in G1 phase. Interestingly, we observe that resistin-exposed cells survive 5-fluorouracil treatment because of a decrease in drug uptake due to the arrest of cells in G1 phase.
Resistin, a proinflammatory cytokine is secreted primarily from macrophages and also from adipocytes in human, whereas in rodents it is secreted mainly from adipocytes [1] . It is a 7.5-kDa cytokine and has a role in many inflammatory pathophysiological disorders including rheumatoid arthritis and cardiovascular diseases [2, 3] . Also, serum resistin level increases gradually in breast, colon, and endometrial cancer patients during tumor progression [4] [5] [6] . Despite a plethora of epidemiological studies demonstrating increased serum resistin in cancer patients, its role on colon cancer cells is yet to be investigated. Additionally, the absence of a definite resistin receptor on the cancer cells poses challenges in deciphering its mode of action.
The elevated level of Toll-like receptor 4 (TLR4) is correlated with poor prognosis in colon cancer patients [7] . TLRs are a family of pattern recognition receptor which were initially known for their function in antigen recognition. The increasing evidences linking cancer to inflammation and emergence of a wide number of endogenous ligands for TLRs predicts their role in cancer. TLR4 is one of the members of this family.
Abbreviations AOM/DSS, azoxymethane/dextran sodium sulfate; CAP1, adenyl cyclase-associated protein; DMEM, Dulbecco's Modified Eagles Medium; MTT, methylene tetrazolium salt; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of transcription 3; TLR4, Toll-like receptor 4. Colon cancer is the third most common cause of cancer death worldwide and is highly prevalent in India [8, 9] . The growth of a cancerous polyp to colon cancer may take 15-20 years [10] . Approximately 50-70% of the colon cancer patients have a loss of function mutation in p53 [11] . It is frequently witnessed that in Azoxymethane/ Dextran sodium sulfate (AOM/DSS) mouse model of colon cancer, specific silencing of suppressor of cytokine signaling 3 (SOCS3) causes increased tumor load [12] .
SOCS family comprises of eight cytoplasmic proteins that are involved in attenuation of cytokine signaling through mediation of a negative feedback loop [13] . SOCS3 is one of the members of the SOCS family which functions by inhibiting the tyrosine kinase activity of JAK2 [14] . It has been reported that continuous activation of JAK2/signal transducer and activator of transcription 3 (STAT3) is responsible for colon cancer cell proliferation [15] . In yet other studies, SOCS3 has been identified as a tumor suppressor in breast cancer cells and in lung cancer it is silenced due to hyper methylation [16, 17] . Also, conditional knockdown of SOCS3 in mice has been shown to promote tumor growth and neovascularization [18] . In colon cancer cells, JAK2/STAT3 pathway is continuously activated. Also, the above mentioned studies suggest that abrogation of SOCS3 is associated with proliferation. Therefore, it is conceivable that inactivation of the JAK2/STAT3 pathway is likely to have an implication on colon cancer growth. In this study, we studied the effect of resistin treatment on SOCS3 level and its consequence on continually activated JAK2/STAT3 pathway. Also, we investigated whether changes in SOCS3 level upon resistin exposure alters proliferation rate of colon cancer cells and does this have any implication in cells exposed to 5-FU.
Materials and methods

Antibodies and chemicals
Soluble human resistin (rhRes) was purchased from Calbiochem (La Jolla, CA, USA). 5-FU methylene tetrazolium salt (MTT) and Propidium iodide were purchased from Sigma (St. Louis, MO, USA). Reduced Growth Factor Basement Membrane Matrix was purchased from Thermo Scientific (Waltham, MA, USA). Recombinant Bovine Insulin was purchased from Sigma. C 14 All those experiments requiring exposure of cells to resistin, cells were starved for 12 h and resistin was added in DMEM containing 1% FBS. Cells were exposed to 100 ngÁmL À1 of resistin for mentioned time periods and media was changed every 24 h. Cells exposed to resistin for 24 h were subsequently treated with 100 nM of insulin for 4 h. Cells were lysed and western blotting was performed. 5-FU treatment (1500 lM) was given to cells pre-exposed to resistin for 48 h in the presence and absence of resistin. and incubated at 37°C. After 24 h, media was supplemented with resistin and cells were cultured for 15 consecutive days along with media change every day. Photographs were taken by Olympus camera and colony sizes were counted using IM-AGE J software (NIH, Bethesda, MD, USA).
Preparation of whole cell lysate and western blotting
Whole-cell lysates were prepared and western blotting was performed as described previously [20] .
Reverse transcription-polymerase chain reaction RNA from vehicle control cells and cells exposed to resistin was extracted using TRIzol TM reagent (Invitrogen) as per the manufacturer's instructions. Total RNA obtained was quantified by measuring absorbance at 260 nm. For cDNA synthesis, 2 lg of total RNA was taken and cDNA synthesis was done as described earlier [21] . qPCR was performed using Mesagreen (Eurogentec, Liege, Belgium) in a LightCycler 480 (Roche Applied Sciences, Penzberg, Germany) using primers: SOCS3:
Immunoprecipitation
Following exposure of cells to resistin, cells were harvested and lysed in RIPA buffer. Equal amount of protein (800 lg) was taken and incubated with anti-TLR4 mouse polyclonal antibody overnight at 4°C in a rotator. Fifteen microliters of protein A/G plus agarose was added in antibody-antigen complex with gentle shaking for 4 h at 4°C. TLR4 and proteins associated with it were disrupted from protein A/G plus agarose beads by adding SDS gel sample buffer. Samples were resolved on SDS/PAGE and processed for western blotting. Cell cycle analysis HCT116 À/À cells were seeded in 35-mm dishes at a density of 0.4 9 10 6 cells/well. After 24 h, cells were starved for 12 h and exposed to resistin for further 24 h. These were harvested and processed for cell cycle analysis as described earlier [19] .
Cross-linking experiment
To determine the percentage of cells in different phases, 10 000 events were counted. Data were analyzed in CELLQUEST PRO Software (BD Biosciences, San Jose, CA, USA).
Immunofluorescence confocal microscopy MC38 cells plated in chambered slides (MP Biomedicals, Santa Ana, CA, USA) were allowed to grow for 24 h. These were transfected with pCMX and pCMXRes plasmids. After 48 h of transfection, cells were fixed in PFA and processed for confocal as described previously [22] . Images were acquired in Leica camera and processed (LAS image analysis software, Leica Microsystems, Wetzlar, Germany).
Indirect ELISA
Resistin level was quantitated in the condition media of pCMXRes-transfected cells by indirect ELISA as described. MC38 cells (1.2 9 10 6 ) were plated in 60-mm dishes.
Postadherence, cells were transfected with pCMX and pCMXRes plasmid. After 24 h of transfection, media was replaced with phenol red-free DMEM and cells were incubated for a further of 24 h. Media was collected and concentrated using lyophiliser (Thermo Fischer Inc). This was reconstituted in PBS. ELISA plates (Becton Dickenson, Franklin Lakes, NJ, USA) were coated with lyophilized and reconstituted media and incubated at 37°C for 4 h. They were then washed with PBS thrice and blocked using 2% BSA in PBS for 1 h at 37°C followed by three washes with PBS. The media-coated plates were incubated with ELISA-specific antibody for resistin, for 4 h at 37°C. Following washing, samples were incubated with HRP-conjugated secondary antibody Drug accumulation assay 
Statistical analysis
SIGMA PLOT 12.0 (Systat Software Inc., San Jose, CA, USA) was used to perform statistical analysis. All data are represented as the mean AE standard deviation (SD). In most experiments, bars represent variations within the wells of an experiment and the experiments were repeated multiple times. Relative fold (RF) values indicated in the blots are average of two independent experiments. Statistical comparison was performed by Student's 2-tailed unpaired t-test.
The values of P < 0.05 were considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
Resistin arrests cells in G1 phase
To study the effect of resistin on colon cancer cell proliferation, we exposed HCT116 indicated a decrease in Cdk4 and Cyclin D1 suggestive of a possible G1 arrest (Fig. 1B) . Increase in percentage of cells in G1 phase was detected in cells exposed to resistin (Fig. 1C) . Moreover, reduced numbers of colonies with smaller size were detected in HCT116
À/À cells chronically exposed to resistin for 15 days (Fig. 1D) .
Transfection of pCMXRes plasmid arrests cells in G1
Overexpression of resistin in mouse colon adenocarcinoma cells, MC38 by transfecting resistin-expressing plasmid, pCMXRes causes increase in cytosolic (Fig. S2 ) and secretory level of resistin ( Fig. 2A) .
Resistin overexpression in MC38 retarded cell proliferation (Fig. 2B) . Furthermore, we observed a reduction in Cdk4 and Cyclin D1 in pCMXRes-transfected cells contributing to G1 arrest (Fig. 2C) . These results ascertain that resistin attenuates progression of cells to S phase by prolonging G1 phase.
Resistin binds to TLR4 on colon cancer cells
In hypothalamic neurons, resistin is reported to bind to TLR4 [23] . Although, no definite receptor for resistin is known, the above cited study stipulates a possible correlation between resistin and TLR4. Therefore, we checked the expression of TLR4 upon exposure of HCT116 À/À cells to resistin. It was observed that TLR4 expression neither changes upon exposure to resistin nor upon transfection of pCMXRes in the cells (Fig. 3A) . Thereafter, we studied resistin-activated signaling pathways. Dose-dependent increase in pERK upon resistin exposure was detected ( ( Fig. S3 ). Because increase in pERK level is linked with stimulation of TLR4-MyD88 pathway, the possibility of interaction between resistin and TLR4 was explored. Therefore, MC38 cells were transfected with pCMXRes to overexpress resistin and treated with sulfo-EGS, a cross-linking agent. Upon western blotting analysis of lysates, we observed that along with unbound TLR4 (95 kDa) and unbound resistin (7.5 kDa), a complex was obtained at 110 kDa consisting of both TLR4 and resistin which binds in a dimeric form (Fig. 3C) suggestive of a complex formation between the two. The functional binding between resistin and TLR4 was verified by immunoprecipitating a complex of TLR4-MyD88 and followed by detection with western blotting analysis. Increased binding of MyD88 to TLR4 in the presence of resistin was observed and the interaction between the two was abrogated upon silencing of TLR4 by its specific siRNA (Fig. 3D) . These findings indicate that resistin functions through TLR4-MyD88 pathway. Furthermore, to validate if the triggering of TLR4 is necessary for resistin-mediated upregulation of pERK, we checked pERK level upon silencing of TLR4 and observed that pERK level remained unchanged upon resistin exposure (Fig. 3E) . 
Resistin upregulates SOCS3 and inhibits constitutively activated JAK2/STAT3 signaling
Recent reports propose a tumor-suppressive role for SOCS3 in AOM/DSS-induced colon tumor formation. SOCS3 is a cytosolic protein the expression of which is regulated by ERK. Also, in literature, resistin is shown to induce SOCS3 expression in 3T3-L1 cells. Therefore, it is likely that resistin-induced expression of SOCS3 may contribute to G1 arrest. To ascertain it, HCT116 À/À cells were exposed to resistin and media supplemented with resistin and anti-resistin antibody together. Resistin and resistin antibody were incubated for 4 h before exposing the cells to the mixture. Also, in one set, resistin and the antibody were premixed and then immunodepleted using protein G beads. In the lysates of the cells treated with resistin, SOCS3 expression was elevated, whereas in the cells where resistin functionality was abrogated by antibody, SOCS3 level remained unchanged (Fig. 4A) . Additionally, qPCR result suggested that resistin exposure up regulates SOCS3 transcript (Fig. S4) .
Maintenance of JAK2/STAT3 in activated status is essential for colon cancer cell proliferation. An increase in SOCS3 diminishes tyrosine phosphorylation of STAT3 at 705 residue, thereby preventing its nuclear localization. Western blot analysis of lysates from cells exposed to resistin indicates that pJAK2 and pSTAT3 levels reduced upon resistin exposure ( Fig. 4B) . Furthermore, by confocal analysis of MC38 cells transfected with pCMXRes, we observed that nuclear localization of STAT3 was diminished confirming, attenuation of JAK2/STAT3 signaling (Fig. 4C) . Growth arrested cells are less likely to respond to mitogenic signals [24] . It has been reported that increased expression of SOCS3 causes decrease in insulin sensitivity of cells [25] . Moreover, insulin is also reported to function as a mitogen to cancer cells [26] . To check if the increased expression of SOCS3 attenuates insulin activated pathways, we treated resistin preexposed cells with insulin and in these cells, insulin failed to induce the tyrosine phosphorylation of IRS-1 (Fig. 4D) . Also, it was noticed that SOCS3 expression was directly regulated by ERK as inhibition of ERK by its pharmacological inhibitor U0126 inhibited resistin-induced SOCS3 levels (Fig. 4E) . Silencing SOCS3 using its siRNA reversed resistin-induced growth arrest in HCT116
À/À cells (Fig. 4F) .
Resistin abrogates response of cells to 5-FU
5-FU, a first-line chemotherapeutic drug is incorporated in rapidly dividing cancer cells. It is used in combination with leucovorin for treating colon cancer patients. We investigated whether there is a difference in sensitivity of cells pre-exposed to resistin compared to those without resistin exposure and treated with 5-FU. Decrease in sensitivity of resistin-exposed cells compared to control cells treated with 5-FU was observed (Fig. 5A) . Furthermore, C 14 -labeled 5-FU uptake experiment indicated less accumulation of 5-FU in resistin-exposed cells as compared to control (Fig. 5B) . These experiments suggest that resistin-treated cells acquire a resistant phenotype to 5-FU. Hsp27 is considered as one of the markers for resistance of colon cancers to 5-FU [27] . We observed an induction in the expression of Hsp27 in cells exposed to resistin (Fig. 5C) . Decreased accumulation of 5-FU and increase in cytoplasmic level of Hsp27 in cells exposed to resistin is likely to contribute to insensitivity of cells to 5-FU. Schematic representation of the proposed model is illustrated in Fig. 5D .
The illustrated model proposes that resistin binds to TLR4 on the surface of colon cancer cells causing increase in phosphorylation of ERK, in a TLR4-MyD88-dependent manner. Elevated pERK level correlates with enhanced transcription of SOCS3 through yet unknown cascade of events. Increase in protein level of SOCS3 blocks JAK2/STAT3 signaling. This causes arrest of cells and prevents cells from responding to insulin-promoted mitogenic signaling.
Discussion
Discovery of resistin by Steppan et al. [1] , as a hormone linking obesity and diabetes, opened avenues for it being investigated for its biological roles. Since then, it has been thoroughly pursued by the scientific community. It is also described as 'found in inflammatory zone' protein. Resistin level increase in pathological conditions such as cardiovascular diseases, rheumatoid arthritis and also in many cancers [4, 6, 28, 29] .
In colon cancer, which is highly prevalent, resistin level correlate with the risk [30] . This association generates curiosity to investigate the plausible interrelation between the two. More than half of the colon cancers have a mutation or loss of function in p53. Therefore, cells with varying p53 status were selected. It was observed that cells with loss of p53 or mutated p53 exhibited a decrease in cell proliferation upon resistin treatment, whereas in cells having functional p53 protein, resistin treatment did not alter growth pattern. Subsequent analysis of resistin-exposed HCT116 Recent studies demonstrate resistin functionality through its binding to one of the following receptors; adenyl cyclase-associated protein (CAP1), decorins, tyrosine protein kinase transmembrane receptor (ROR1), and Toll-like receptor-4 in various models [31] [32] [33] [34] . Activation of CAP1 promotes proliferation and metastatic potential of breast cancer cells but there are no reports demonstrating its presence or function in colon tumors. Immunohistochemical analysis of decorin receptor revealed that the expression of this protein decreases with the progression of tumor [35] . Also, the level of resistin increases as the tumor progresses. As decorin level decreases with progression of colon cancer while resistin level increase, because of this inverse correlation it is unlikely that decorin will function as a resistin receptor. Subsequently, the search was narrowed down to two probable resistin receptors, ROR1 and TLR4, in this study. Microarray analysis of tumor tissues documents ROR1 upregulation in colon, lung, and pancreatic cancers [36] . Furthermore, when ROR1 is switched on upon binding to its ligand, it concomitantly activates pAKT signaling [37] . Interestingly, upon exposure of HCT116 À/À cells to varying doses of resistin, an increase in pERK and no change in pAKT were detected. This result suggests that it is unlikely that ROR1 is the receptor for resistin in these cancer cells. Also, it suggests that the involved receptor upon being turn on must invoke pERK signal, which shifted the attention to TLR4, shown to act through upregulation of pERK.
TLR4 is associated with various functions in colorectal cancers [38] . Upon binding to its ligand, it either acts in a MyD88 dependent or independent pathways causing phosphorylation of ERK. Co-immunoprecipitation of resistin-exposed cells indicated interaction between TLR4 and MyD88 in the presence of resistin. Also, this interaction decreased when TLR4 was silenced by its siRNA. The specific interaction between TLR4 and resistin was further detected by cross-linking assay that demonstrated interaction of TLR4 with resistin (TLR4-Res). One of the transcription factors for SOCS3 gene is ATF2. ATF2 in turn gets phosphorylated and localizes in the nucleus upon phosphorylation of ERK [39, 40] . Therefore, it is likely that pERK might be activating ATF2 and upregulating SOCS3. Increase in the level of SOCS3 inhibits JAK2/STAT3 signaling arresting the cells in G1 phase and also imparting resistance to growth/metabolic signal initiated by insulin. G1 arrest in the presence of resistin causes a decrease in the uptake of 5-FU and minimizes its toxic effects, allowing cells to survive and grow. The observation that Hsp27 increases upon resistin exposure further validates the findings that resistinexposed cells acquire a resistant phenotype to 5-FU.
Numerous studies indicate that solid tumors are heterogenous and in addition to cancer cells, fibroblasts, endothelial cells, leukocytes, and macrophages are also present [41] . In studies by Solinas et al., and Gyorki and Lindeman, it has been reported that nearly 50% of the solid tumor mass is contributed by tumorassociated macrophages [42, 43] . Along with the grade of tumor, the macrophage infiltration increases and macrophages secrete resistin [44] . Based on these reports, it is conceivable that the increase in serum resistin with the increase in grade of colon tumor is likely to be a function of extensive macrophage infiltration. It is evident from our data that resistin exposure arrests cells in G1 phase thereby prolonging it and causing delay in progression of p53 nonfunctional colon cancer cells. Also, since it is well known that colon cancer development and progression takes a long time, 15-20 years [10] , our findings that resistin slows down colon cancer cell growth may have contributory role toward delay in colon cancer progression.
Data obtained from these experiments demonstrate that in p53 nonfunctional cells resistin induces G1 arrest. Resistin binds to TLR4 on colon cancer cells and activates TLR4-MyD88-dependent pathway further switching on ERK signaling. Activated ERK promotes upregulation of SOCS3, which functions as a negative feedback regulator and shuts down JAK2/ STAT3 signaling resulting in growth arrest.
Clinical studies in colon cancer patients with increased TLR4 expression parallels with poor prognosis and therapy response [45] . Since these studies do not detail the resistin level and the status of p53 in tumors, it restricts us from drawing any conclusion to validate this relation. Based on in vitro findings presented here, it can be speculated that binding of resistin to TLR4 promotes G1 arrest and arrested p53 null cells are less likely to incorporate 5-FU as it is a drug which gets incorporated into DNA of rapidly dividing cancer cells, thereby making it less effective. Controlling the effect of resistin may have implications in promoting 5-FU induced death in tumor cells harboring non-functional p53.
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